Stock events for Kodiak Sciences, Inc. (KOD)
Over the past six months, Kodiak Sciences' stock was impacted by several events. In December 2025, the company closed an upsized public offering of common stock, raising approximately $184 million. New data from the Phase 1b APEX study for KSI-101 in macular edema secondary to inflammation (MESI) was presented in September 2025 and February 2026. In November 2025, Kodiak Sciences reported Q3 2025 results, highlighting clinical progress for KSI-101, KSI-501, and tarcocimab. The company participated in scientific conferences in September 2025 and the J.P. Morgan Healthcare Conference in January 2026. KOD's share price has been volatile over the past three months compared to the US market, although its weekly volatility decreased from 17% to 12% over the past year.
Demand Seasonality affecting Kodiak Sciences, Inc.’s stock price
Based on the nature of Kodiak Sciences' products, there is no inherent demand seasonality. Demand for therapies is generally consistent throughout the year, driven by disease prevalence rather than seasonal factors.
Overview of Kodiak Sciences, Inc.’s business
Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for retinal diseases. Founded in 2009 and headquartered in Palo Alto, California, the company utilizes its proprietary Antibody Biopolymer Conjugate (ABC) Platform. Its pipeline includes Tarcocimab tedromer (KSI-301) for retinal vascular diseases, KSI-501 targeting IL-6 and VEGF for retinal diseases with inflammation, KSI-101 for retinal fluid and inflammation, KSI-201 for resistant wet AMD, KSI-401 for dry AMD, and KSI-601 for dry AMD.
KOD’s Geographic footprint
Kodiak Sciences Inc. is headquartered in Palo Alto, California, United States. The company aims to enhance its presence in North American and European markets and is actively exploring opportunities to launch additional products globally.
KOD Corporate Image Assessment
In the past year, Kodiak Sciences' brand reputation has seen a positive shift due to encouraging clinical data, with the stock experiencing a "stellar move" off its 52-week low in April 2025. Positive news regarding KSI-101's efficacy in treating macular edema secondary to inflammation (MESI) has been highlighted. The company's commitment to advancing its pipeline and its "Kodiak 2.0" strategy has been a key message. However, the company has faced past setbacks, such as the initial discontinuation of tarcocimab's development in July 2023. Analyst opinions on healthcare stocks, including Kodiak Sciences, have been mixed.
Ownership
Kodiak Sciences Inc. has significant institutional ownership. As of December 2025, there were 152 active institutional owners and shareholders, holding a total of 54.73 million shares, representing 103.3% of the company. Major institutional owners include Baker Bros. Advisors Lp, BlackRock, Inc., and Vanguard Group Inc. Individual ownership accounts for approximately 4.78% of the company's shares, with key insiders including Dr. Victor Perlroth and Dr. Richard S. Levy.
